ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0152

Antibody Response Post SARS-CoV-2 Vaccination in Kidney Transplant Recipients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Butiu, Maria, University of Washington, Seattle, Washington, United States
  • Leca, Nicolae, University of Washington, Seattle, Washington, United States
  • Bakthavatsalam, Ramasamy, University of Washington, Seattle, Washington, United States
Background

This project aims to analyze the proportion of patients who did not develop antibodies following COVID-19 vaccination and to ensure that the immune stimulation secondary to the vaccine is not associated with clinical rejection and DSA development.

Methods

Samples collected from COVID-19 vaccinated kidney transplant recipients from 3/1/21-4/26/21 were tested for DSA and COVID-19 antibodies using a multi-antigen detection Luminex platform (BioRad). The following were tested: receptor binding domain IgG, spike 1 IgG, spike 2 IgG, nucleocapsid IgG.

Results

94 patients were included in this study. 57% had no antibodies post second dose of COVID-19 vaccination. This number decreased to 52% when looking at samples collected >2 weeks after the final vaccine dose. Of all positive patients, 19% showed evidence of previous COVID-19 infection based on nucleocapsid positivity, which if excluded from the cohort analysis, lead to a higher rate of patients not responding to the vaccine. We did not observe a correlation between antibody positivity and demographics or clinical characteristics. Only 2 patients developed new DSA post-vaccination(avg MFI 1600). No episodes of clinical rejection were noted. 10 patients provided multiple samples, of which 5 had positive antibodies with an average decrease of 17 U/mL for S1 IgG per week.

Conclusion

When excluding patients previously infected with COVID-19, the rate of positive antibody formation post vaccine is 35%.
More research needs to be done to understand the correlation of antibody response and protection against COVID-19 infection.

Demographics and Clinical Characteristics

Average Antibody Titers